Raymond James Downgrades Guaranty Bancshares to Market Perform
Raymond James analyst Michael Rose downgrades Guaranty Bancshares (NASDAQ:GNTY) from Outperform to Market Perform.
BTIG Downgrades T2 Biosystems to Neutral
BTIG analyst Mark Massaro downgrades T2 Biosystems (NASDAQ:TTOO) from Buy to Neutral.
B of A Securities Downgrades Kohl’s to Underperform, Lowers Price Target to $26
B of A Securities analyst Lorraine Hutchinson downgrades Kohl's (NYSE:KSS) from Neutral to Underperform and lowers the price target from $50 to $26.
Baird Downgrades Aspen Technology to Neutral, Lowers Price Target to $162
Baird analyst Rob Oliver downgrades Aspen Technology (NASDAQ:AZPN) from Outperform to Neutral and lowers the price target from $170 to $162.
Keybanc Downgrades Vtex to Sector Weight
Keybanc analyst Josh Beck downgrades Vtex (NYSE:VTEX) from Overweight to Sector Weight.
UBS Downgrades Kellogg to Neutral, Lowers Price Target to $74
UBS analyst Cody Ross downgrades Kellogg (NYSE:K) from Buy to Neutral and lowers the price target from $81 to $74.
Citigroup Downgrades Consolidated Comms Hldgs to Sell, Announces $5 Price Target
Citigroup analyst Michael Rollins downgrades Consolidated Comms Hldgs (NASDAQ:CNSL) from Neutral to Sell and announces $5 price target.
Wells Fargo Downgrades Bank OZK to Equal-Weight, Lowers Price Target to $42
Wells Fargo analyst Jared Shaw downgrades Bank OZK (NASDAQ:OZK) from Overweight to Equal-Weight and lowers the price target from $58 to $42.
Jefferies Downgrades Applied Molecular to Hold
Jefferies analyst Chris Howerton downgrades Applied Molecular (NASDAQ:AMTI) from Buy to Hold.
Mizuho Downgrades CytomX Therapeutics to Neutral, Lowers Price Target to $4
Mizuho analyst Mara Goldstein downgrades CytomX Therapeutics (NASDAQ:CTMX) from Buy to Neutral and lowers the price target from $16 to $4.